等待开盘 11-17 09:30:00 美东时间
+0.360
+12.54%
Lexeo Therapeutics, Inc. ( ($LXEO) ) has provided an update. On November 16, 20...
11-16 21:27
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.33) by 30.3 percent. This is a 30.3 percent decrease over losses of $(0.33) per share from the same period last year.
11-16 20:02
Lexeo Therapeutics will report Q3 2026 financial results and provide an update on its HEROIC-PKP2 Phase I/II trial for LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy (ACM), on November 16, 2026. A webcast will be held at 8:00 AM ET, accessible via the company's website. LX2020, designed to deliver a functional PKP2 gene to cardiomyocytes, has received FDA designations including Regenerative Medicine Advanced Therapy and Fast Track....
11-15 12:00
11月10日,Lexeo Therapeutics(LXEO)收涨8.65%,报3.14美元,成交额416.38万美元,市值2.58亿美元。 行情数据 • 开盘...
11-10 07:33
11月3日,Lexeo Therapeutics(LXEO)收跌2.55%,报3.06美元,成交额373.37万美元,市值2.51亿美元。 行情数据 • 开盘价...
11-03 07:30
Lexeo Therapeutics announced multiple presentations at AHA and ICAR 2026, highlighting their cardiovascular and neurological gene therapy programs. Key updates include LX2006 demonstrating sustained neurologic and cardiac benefits in Friedreich ataxia, with mFARS scores improving by 2.13 points annually and further gains at 36 months. AHA presentations will showcase preclinical data on LX2021 for desmoplakin cardiomyopathy and LX2020 for TNNI3 ca...
11-02 12:00
10月27日,Lexeo Therapeutics(LXEO)收跌3.57%,报2.7美元,成交额314.95万美元,市值2.22亿美元。 行情数据 • 开盘价...
10-27 06:37
Lexeo Therapeutics will host an investor event on October 21, 2026, at 1:00 PM ET, discussing clinically meaningful arrhythmias in PKP2-ACM. Narinder Bhalla, M.D., Lexeo's Chief Medical Officer, and Alessio Gasperetti, M.D., Ph.D., a cardiologist specializing in inherited arrhythmias, will address key assessments, guideline-based approaches, and disease progression in PKP2-ACM. The event will be webcast live on Lexeo's website, with a replay avai...
10-19 11:00
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:41
Lexeo Therapeutics announced that its LX2006 gene therapy abstract has been accepted for an oral presentation at the International Congress of Parkinson’s Disease and Movement Disorders 2026 in Seoul. The presentation will highlight early neurologic improvements in Friedreich ataxia patients treated with LX2006, including new mFARS subscore analyses, and its potential to address the multisystem burden of the disease. LX2006, an AAV-based therapy,...
10-01 13:00